Funder
Crohn's and Colitis Foundation of America
Publisher
Springer Science and Business Media LLC
Reference40 articles.
1. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785-94. https://doi.org/10.1053/j.gastro.2011.01.055.
2. Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. The American journal of gastroenterology. 2005;100(11):2478-85. https://doi.org/10.1111/j.1572-0241.2005.00248.x.
3. Hanauer S, Schwartz J, Robinson M, Roufail W, Arora S, Cello J et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. The American journal of gastroenterology. 1993;88(8):1188-97.
4. Hanauer SB, Sninsky CA, Robinson M, et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group. Ann Intern Med. 1996;124(2):204-11. https://doi.org/10.7326/0003-4819-124-2-199601150-00003.
5. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60(5):571-607. https://doi.org/10.1136/gut.2010.224154.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献